Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice took place Oct. 3-5, 2018, in Dubrovnik, Croatia.

The challenges of diagnosing CMML

Print Friendly, PDF & Email


Micrograph showing CMML
Image by Simon Caulton
Diagnosing chronic myelomonocytic leukemia (CMML) remains a challenge in 2018, according to a presentation at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. Even with updated World Health Organization (WHO) criteria, karyotyping, and genetic analyses, it can be difficult to distinguish CMML from other conditions,... [Read Article]
Print Friendly, PDF & Email

Optimizing use of TKIs in CML

Print Friendly, PDF & Email


Hagop Kantarjian, MD
Long-term efficacy and toxicity should inform decisions about tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), according to the keynote presenter at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. Studies have indicated that long-term survival rates are similar whether CML patients receive frontline treatment with imatinib... [Read Article]
Print Friendly, PDF & Email

CDK8 inhibitor can fight AML, though it’s unclear how

Print Friendly, PDF & Email


Eliza Majewska, PhD
The CDK8 inhibitor SEL120 has demonstrated preclinical activity against acute myeloid leukemia (AML), but the agent’s mechanism of action is still unclear. Researchers found that several AML cell lines were “highly sensitive” to SEL120, and the inhibitor was active in primary patient samples. SEL120 also reduced tumor growth in mouse models... [Read Article]
Print Friendly, PDF & Email

GPS appears to predict survival in myelofibrosis

Print Friendly, PDF & Email


Marko Lucijanić, MD, PhD
The Glasgow Prognostic Score (GPS) may predict survival in patients with myelofibrosis (MF), according to research presented at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. In a retrospective study, MF patients who were considered intermediate-risk according to the GPS had roughly twice the risk of death... [Read Article]
Print Friendly, PDF & Email

Variant not associated with CLL, AIHA, or ITP in certain patients

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or autoimmune hematologic disorders in patients from the Republic of Macedonia. Past studies have shown an association between the PTPN22 R620W variant and both CLL and autoimmune diseases in patients from... [Read Article]
Print Friendly, PDF & Email

System may better predict thrombosis in lymphoma

Print Friendly, PDF & Email


Audience at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice
An updated scoring system can more accurately identify lymphoma patients who may require thromboprophylaxis, according to researchers. The revised scoring system, ThroLy, proved more effective than other systems for predicting thromboembolic events in lymphoma patients. Researchers found the updated ThroLy had... [Read Article]
Print Friendly, PDF & Email